Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxelis Hepatitis B Protection Durability Challenge Study
NCT04490499Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of DTaP-IPV-Hep B-PRP-T vaccine in hepatitis B (HBV), sponsored by Merck & Co.. Started Sep 2020; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04490499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490499.